Search Result

Isoforms Recommended:	CYP3A CYP3

Results for "

CYP3A

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Antibiotic (3) Autophagy (7) Bacterial (5) COX (1) Cytochrome P450 (37) Drug Metabolite (4) Endogenous Metabolite (3) Ferroptosis (1) Fungal (2) Glucocorticoid Receptor (2) GnRH Receptor (1) Histamine Receptor (1) HIV (3) Isotope-Labeled Compounds (3) P-glycoprotein (1) Potassium Channel (3) Reactive Oxygen Species (2) Small Interfering RNA (siRNA) (4) Thrombopoietin Receptor (5) Virus Protease (2)
By Research Areas:	Cancer (15) Cardiovascular Disease (6) Endocrinology (3) Infection (12) Inflammation/Immunology (14) Metabolic Disease (19) Neurological Disease (1)
Oligonucleotides:	Human Pre-designed siRNA Sets (4) siRNAs (4)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-130353

Desethylamiodarone hydrochloride N-desethylamiodarone hydrochloride; LB 33020 hydrochloride	Potassium Channel Autophagy	Cardiovascular Disease
Desethylamiodarone hydrochloride (N-desethylamiodarone hydrochloride) is a major active metabolite of Amiodarone. Desethylamiodarone hydrochloride is formed by CYP3A isoenzymes. Amiodarone is an antiarrhythmic agent for inhibition of ATP-sensitive potassium channel with an IC₅₀ of 19.1 μM ^[3].

HY-150580

CYP3A4-IN-2	Cytochrome P450	Inflammation/Immunology Cancer
CYP3A4-IN-2 is a specific inhibitor of cytochrome P450 3A4 (CYP3A4) with the IC₅₀ value of 0.055 μM. CYP3A4-IN-2 is a ritonavir analogue with increased hydrophobicity of the R2 side group and stronger inhibitory effect compared to ritonavir. CYP3A4-IN-2 can be used as an antiviral agent and immunosuppressants .

HY-150581

CYP3A4-IN-3	Cytochrome P450	Infection Inflammation/Immunology
CYP3A4-IN-3 is a high-affinity specific inhibitor of cytochrome P450 3A4 (CYP3A4) with the IC₅₀ value of 0.075 μM. CYP3A4-IN-3 is a ritonavir analogue, but with a simpler structure and twice the inhibitory effect of ritonavir. CYP3A4-IN-3 is used as an antiviral agent and immunosuppressant .

HY-150574

CYP3A4-IN-1	Cytochrome P450	Infection
CYP3A4-IN-1 (compound 5a) is a potent cytochrome P450 3A4 (CYP3A4) inhibitor with an IC₅₀ value of 0.085 µM .

HY-169217

CYP3A4-IN-4	Cytochrome P450	Cancer
CYP3A4-IN-4 (compound Δ,Λ-3), a Ru(II)−Ir(III) Conjugate, is a photoactive inhibitor of the major human drug metabolizing enzyme *CYP3A4. CYP3A4-IN-4 containing the [Ru(tpy)(Me₂bpy)] photocaging group showed an IC₅₀ of 2.2 μM for inhibition of microsomal CYP3A4 under light conditions (λ_irr=530 nm, t_irr=15 min). CYP3*A4-IN-4 shows the phototherapeutic index (PI) for of 5.4 .

HY-146177

CYP3A4 enzyme-IN-1	Bacterial Cytochrome P450	Infection
CYP3A4 enzyme-IN-1 (compound 59) is a potent antibacterial agent, with a MIC of 1 μg/mL for MRSA. CYP3A4 enzyme-IN-1 exhibits low to moderate inhibitory effects on CYP1A2, CYP2E1, CYP2D6, and CYP3A4 enzymes .

HY-RS03472

CYP3A43 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CYP3A43 Human Pre-designed siRNA Set A contains three designed siRNAs for CYP3A43 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CYP3A43 Human Pre-designed siRNA Set A CYP3A43 Human Pre-designed siRNA Set A

HY-RS03471

CYP3A4 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CYP3A4 Human Pre-designed siRNA Set A contains three designed siRNAs for CYP3A4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CYP3A4 Human Pre-designed siRNA Set A CYP3A4 Human Pre-designed siRNA Set A

HY-RS03474

CYP3A7 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CYP3A7 Human Pre-designed siRNA Set A contains three designed siRNAs for CYP3A7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CYP3A7 Human Pre-designed siRNA Set A CYP3A7 Human Pre-designed siRNA Set A

HY-RS03473

CYP3A5 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CYP3A5 Human Pre-designed siRNA Set A contains three designed siRNAs for CYP3A5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CYP3A5 Human Pre-designed siRNA Set A CYP3A5 Human Pre-designed siRNA Set A

HY-10493

Cobicistat Maximum Cited Publications 11 Publications Verification GS-9350	Cytochrome P450 HIV	Infection Cancer
Cobicistat is a potent and selective inhibitor of *cytochrome P450 3A (CYP3A) enzymes* with IC₅₀s of 30-285 nM. Cobicistat is a pharmacokinetic enhancer which increases the overall absorption of several HIV medications.

HY-137789

Tazofelone LY 213829	COX	Cancer
Tazofelone (LY 213829) is a cyclooxygenase-II (COX-II) inhibitor. Tazofelone transform into sulfoxide and quinol metabolites is primarily mediated by CYP3A. Tazofelone can be used for the research of inflammatory bowel disease .

HY-113327

1,3,7-Trimethyluric acid	Endogenous Metabolite	Cancer
1,3,7-Trimethyluric acid is the metabolite of caffeine. The metabolic ratio 1,3,7-Trimethyluric acid to caffeine can be evaluated as a biomarker to describe variability in CYP3A activity in a cohort .

HY-W019847

Azamulin	Cytochrome P450	Infection Metabolic Disease
Azamulin is an irreversible, highly selective inhibitior of human *CYP3Aa. Azamulin has CYP3A inhibition activity with IC₅₀* values range from 0.03-0.24 μM. Azamulin can be used for the research of metabolism and antiinfection .

HY-10493R

Cobicistat (Standard)	Cytochrome P450 HIV	Infection Cancer
Cobicistat (Standard) is the analytical standard of Cobicistat. This product is intended for research and analytical applications. Cobicistat is a potent and selective inhibitor of *cytochrome P450 3A (CYP3A) enzymes* with IC₅₀s of 30-285 nM. Cobicistat is a pharmacokinetic enhancer which increases the overall absorption of several HIV medications.

HY-10493S

Cobicistat-d8 GS-9350-d₈	Isotope-Labeled Compounds HIV Cytochrome P450	Infection
Cobicistat-d8 (GS-9350-d8) is a deuterated version of Cobicistat (HY-10493). Cobicistat is a potent and selective inhibitor of cytochrome P450 3A (CYP3A) with IC₅₀ values of 30-285 nM. Cobicistat is a pharmacokinetic enhancer that enhances the absorption of anti-HIV active molecules ^[3].

HY-113482

1β-Hydroxydeoxycholic acid 1β-OH-DCA	Endogenous Metabolite Cytochrome P450	Metabolic Disease
1β-Hydroxydeoxycholic acid (1β-OH-DCA), a secondary bile acid, is a CYP3A biomarker. Deoxycholic acid is specifically metabolized into 1β-Hydroxydeoxycholic acid by CYP3A4 and CYP3A7 using recombinant human CYP450 enzymes .

HY-W040468

2-Phenyl-2-(1-piperidinyl)propane	Cytochrome P450	Metabolic Disease
2-Phenyl-2-(1-piperidinyl)propane is a selective and reversible human *CYP2B6* inhibitor with an IC₅₀ of 5.1 μM and a K_i of 5.6. 2-Phenyl-2-(1-piperidinyl)propane inhibits CYP2D6 (IC₅₀=74 μM), CYP3A (IC₅₀=200 μM) .

HY-N0693

Schisandrin A 5+ Cited Publications Schizandrin-A; Wuweizisu-A; Deoxyschizandrin	Cytochrome P450 Autophagy Virus Protease	Inflammation/Immunology Cancer
Schisandrin A inhibits *CYP3A* activity with an IC₅₀ of 6.60 μM and K_i of 5.83 μM, respectively.

HY-108881

Troleandomycin Triacetyloleandomycin	Cytochrome P450 Bacterial	Infection Inflammation/Immunology
Troleandomycin (Triacetyloleandomycin), a macrolide acrolide antibiotic, is a selective *CYP3A* inhibitor. Troleandomycin is an oral corticosteroid for asthma study ^[3].

HY-100902

CDD3506	Cytochrome P450	Metabolic Disease
CDD3506 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic cytochrome P450IIIA (CYP3A) activity.

HY-100901

CDD3505	Cytochrome P450	Metabolic Disease
CDD3505 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic cytochrome P450IIIA (CYP3A) activity.

HY-117580

16α-Hydroxyprednisolone OH-PRED	Drug Metabolite	Inflammation/Immunology
16α-Hydroxyprednisolone is a stereoselective metabolite of the 22(R) epimer of the glucocorticoid budesonide via cytochrome P450 3A (CYP3A) enzymes .

HY-N0693R

Schisandrin A (Standard)	Cytochrome P450 Autophagy Virus Protease	Inflammation/Immunology Cancer
Schisandrin A (Standard) is the analytical standard of Schisandrin A. This product is intended for research and analytical applications. Schisandrin A inhibits CYP3A activity with an IC₅₀ of 6.60 μM and Ki of 5.83 μM, respectively.

HY-118216

Bitertanol Biloxazol	Fungal Cytochrome P450	Infection
Bitertanol (Biloxazol) is a potent antifungal agent. Bitertanol also is an *CYP1A1, CYP2B, and CYP3A* inducer in vivo and an *CYP1A* inhibitor in vitro .

HY-107534

AG-045572	GnRH Receptor	Endocrinology
AG-045572 is a GnRH receptor antagonist with K_is of 6.0 nM and 3.8 nM for human and rat GnRH receptor, respectively. AG-045572 is metabolized by CYP3A and ressuppresses testosterone .

HY-135175

Phenoprolamine hydrochloride	Adrenergic Receptor	Cardiovascular Disease Neurological Disease
Phenoprolamine hydrochloride is an adrenergic α1 receptor antagonist that exhibits potent antihypertensive effects. Phenoprolamine hydrochloride demonstrates neuroprotective and cardioprotective properties. Phenoprolamine hydrochloride inhibits CYP2D and CYP3A activities while down-regulating their mRNA transcription.

HY-151239

ONT-993 AR 00440993	Cytochrome P450	Cancer
ONT-993 is an aliphatic hydroxylated metabolite. ONT-993 inhibits *CYP2D6* (IC₅₀=7.9 µM) and causes metabolism-dependent inactivation of CYP3A (KI=1.6 µM) .

HY-118216R

Bitertanol (Standard)	Fungal Cytochrome P450	Infection
Bitertanol (Standard) is the analytical standard of Bitertanol. This product is intended for research and analytical applications. Bitertanol (Biloxazol) is a potent antifungal agent. Bitertanol also is an CYP1A1, CYP2B, and CYP3A inducer in vivo and an CYP1A inhibitor in vitro .

HY-130353S

Desethyl Amiodarone-d4 hydrochloride	Isotope-Labeled Compounds Potassium Channel Autophagy	Cardiovascular Disease
Desethyl Amiodarone-d₄ (hydrochloride) is the deuterium labeled Desethylamiodarone hydrochloride. Desethylamiodarone hydrochloride (N-desethylamiodarone hydrochloride) is a major active metabolite of Amiodarone. Desethylamiodarone hydrochloride is formed by CYP3A isoenzymes. Amiodarone is an antiarrhythmic agent for inhibition of ATP-sensitive potassium channel with an IC50 of 19.1 μM[1][2][3].

HY-117580S

16α-Hydroxyprednisolone-d3 OH-PRED-d₃	Drug Metabolite	Inflammation/Immunology
16α-Hydroxyprednisolone-d₃ is the deuterium labeled 16α-Hydroxyprednisolone. 16α-Hydroxyprednisolone is a stereoselective metabolite of the 22(R) epimer of the glucocorticoid budesonide via cytochrome P450 3A (CYP3A) enzymes[1][2].

HY-130353R

Desethylamiodarone (hydrochloride) (Standard) N-desethylamiodarone (hydrochloride)(Standard); LB 33020 (hydrochloride) (Standard)	Potassium Channel Autophagy	Cardiovascular Disease
Desethylamiodarone (hydrochloride) (Standard) is the analytical standard of Desethylamiodarone (hydrochloride). This product is intended for research and analytical applications. Desethylamiodarone hydrochloride (N-desethylamiodarone hydrochloride) is a major active metabolite of Amiodarone. Desethylamiodarone hydrochloride is formed by CYP3A isoenzymes. Amiodarone is an antiarrhythmic agent for inhibition of ATP-sensitive potassium channel with an IC₅₀ of 19.1 μM ^[3].

HY-N0692

Schisandrol B 2 Publications Verification Gomisin-A; TJN-101; Wuweizi alcohol-B	Reactive Oxygen Species Cytochrome P450 Autophagy	Cancer
Schisandrol B (Gomisin-A) is a major active constituent of Schisandra chinensis with hepato-protective effects. Schisandrol B inhibits reactive oxygen species (ROS) production. Schisandrol B inhibits the activity of P-glycoprotein and *CYP3A* and also has anti-inflammatory, anti-diabetic and antioxidant activities ^[3].

HY-117580R

16α-Hydroxyprednisolone (Standard)	Drug Metabolite	Inflammation/Immunology
16α-Hydroxyprednisolone (Standard) is the analytical standard of 16α-Hydroxyprednisolone. This product is intended for research and analytical applications. 16α-Hydroxyprednisolone is a stereoselective metabolite of the 22(R) epimer of the glucocorticoid budesonide via cytochrome P450 3A (CYP3A) enzymes .

HY-B1127R

Betamipron (Standard)	Bacterial Antibiotic	Others
16α-Hydroxyprednisolone (Standard) is the analytical standard of 16α-Hydroxyprednisolone. This product is intended for research and analytical applications. 16α-Hydroxyprednisolone is a stereoselective metabolite of the 22(R) epimer of the glucocorticoid budesonide via cytochrome P450 3A (CYP3A) enzymes .

HY-N1457

Chrysosplenetin	P-glycoprotein Cytochrome P450 Ferroptosis	Metabolic Disease
Chrysosplenetin is one of the polymethoxylated flavonoids in Artemisia annua L. (Compositae) and other several Chinese herbs. Chrysosplenetin inhibits P-gp activity and reverses the up-regulated P-gp and MDR1 levels induced by artemisinin (ART). Chrysosplenetin significantly augments the rat plasma level and anti-malarial efficacy of ART, partially due to the uncompetitive inhibition effect of Chrysosplenetin on rat *CYP3A* .

HY-16718

Dagrocorat PF-00251802	Glucocorticoid Receptor Cytochrome P450	Inflammation/Immunology Endocrinology
Dagrocorat (PF-00251802) is an orally active and selective high-affinity partial agonist of the glucocorticoid receptor. Dagrocorat is also a time-dependent reversible inhibitor of *CYP3A* (IC₅₀=1.3 μM in human liver microsomes) and *CYP2D6* (K_i=0.57 μM in human liver microsomes). Dagrocorat can be used for the research of rheumatoid arthritis .

HY-16718A

Dagrocorat hydrochloride PF-00251802 hydrochloride	Glucocorticoid Receptor Cytochrome P450	Inflammation/Immunology Endocrinology
Dagrocorat (PF-00251802) hydrochloride is an orally active and selective high-affinity partial agonist of the glucocorticoid receptor. Dagrocorat hydrochloride is also a time-dependent reversible inhibitor of *CYP3A* (IC₅₀=1.3 μM in human liver microsomes) and *CYP2D6* (K_i=0.57 μM in human liver microsomes). Dagrocorat hydrochloride can be used for the research of rheumatoid arthritis .

HY-13463A

Avatrombopag maleate 3 Publications Verification AKR-501 maleate; E5501 maleate; YM477 maleate	Thrombopoietin Receptor	Inflammation/Immunology
Avatrombopag maleate (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC₅₀=3.3 nM). Avatrombopag maleate mimics the biological activities of TPO. Avatrombopag maleate increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag maleate is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A ^[3].

HY-13463

Avatrombopag 3 Publications Verification AKR-501; E5501; YM477	Thrombopoietin Receptor	Inflammation/Immunology Cancer
Avatrombopag (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC₅₀=3.3 nM). Avatrombopag mimics the biological activities of TPO. Avatrombopag increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A ^[3].

HY-13463B

Avatrombopag hydrochloride 3 Publications Verification AKR-501 hydrochloride; E5501 hydrochloride; YM477 hydrochloride	Thrombopoietin Receptor	Cardiovascular Disease Cancer
Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC₅₀=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A ^[3].

HY-N0692R

Schisandrol B (Standard)	Reactive Oxygen Species Cytochrome P450 Autophagy	Cancer
Schisandrol B (Standard) is the analytical standard of Schisandrol B. This product is intended for research and analytical applications. Schisandrol B (Gomisin-A) is a major active constituent of Schisandra chinensis with hepato-protective effects. Schisandrol B inhibits reactive oxygen species (ROS) production. Schisandrol B inhibits the activity of P-glycoprotein and CYP3A and also has anti-inflammatory, anti-diabetic and antioxidant activities ^[3].

HY-N7454

Anhydroerythromycin A	Antibiotic Bacterial	Infection
Anhydroerythromycin A is a degradation product of the macrolide antibiotic erythromycin. Anhydroerythromycin A is formed via degradation of erythromycin in acidic aqueous solutions in vitro as well as in vivo. Anhydroerythromycin A is active against S. aureus and B. cereus in vitro (MICs = 12.5 and 6.25 μg/ml, respectively). Anhydroerythromycin A also inhibits steroid 6β-hydroxylase activity associated with the cytochrome P450 (CYP) isoform CYP3A in human liver microsomes.

HY-13463R

Avatrombopag (Standard)	Thrombopoietin Receptor	Inflammation/Immunology Cancer
Avatrombopag (Standard) is the analytical standard of Avatrombopag. This product is intended for research and analytical applications. Avatrombopag (AKR-501) is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC₅₀=3.3 nM). Avatrombopag mimics the biological activities of TPO. Avatrombopag increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A ^[3].

HY-N7454R

Anhydroerythromycin A (Standard)	Antibiotic Bacterial	Infection
Anhydroerythromycin A (Standard) is the analytical standard of Anhydroerythromycin A. This product is intended for research and analytical applications. Anhydroerythromycin A is a degradation product of the macrolide antibiotic erythromycin. Anhydroerythromycin A is formed via degradation of erythromycin in acidic aqueous solutions in vitro as well as in vivo. Anhydroerythromycin A is active against S. aureus and B. cereus in vitro (MICs = 12.5 and 6.25 μg/ml, respectively). Anhydroerythromycin A also inhibits steroid 6β-hydroxylase activity associated with the cytochrome P450 (CYP) isoform CYP3A in human liver microsomes.

HY-13463BS

Avatrombopag-d8 hydrochloride AKR-501-d₈ hydrochloride; E5501-d₈ hydrochloride; YM477-d₈ hydrochloride	Isotope-Labeled Compounds Thrombopoietin Receptor	Cardiovascular Disease
Avatrombopag-d₈ (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A[1][2][3].

HY-124626

(R)-(+)-Mequitazine	Histamine Receptor	Inflammation/Immunology
(R)-(+)-Mequitazine is a histamine H1 receptor antagonist that mainly undergoes bio-transformation via human liver microsomes, resulting in hydroxylated and S-oxidized metabolites. (R)-(+)-Mequitazine competitively binds to the H1 receptors in gastrointestinal, vascular, and respiratory effect cells, thus blocking the endogenous activity of histamine. (R)-(+)-Mequitazine has an inhibitory effect on CYP3A-catalyzed midazolam 1’-hydroxylase. (R)-(+)-Mequitazine can be used in the study of various allergic diseases .

HY-E70491

*Human CYP3A5,High-Reductase*	Cytochrome P450	Metabolic Disease
Human CYP3A5, High-Reductase, a recombinant CYP3A5, is a member of the CYP enzyme family. CYP3A5 is mainly expressed in the prostate and the liver .

HY-E70458

*Human CYP3A4,High-Reductase*	Cytochrome P450	Metabolic Disease
Human CYP3A4, High-Reductase, a recombinant CYP3A4, is a multifunctional enzyme with a wide range of substrates .

HY-E70496

*Human CYP3A7,Low-Reductase*	Cytochrome P450	Metabolic Disease
Human CYP3A7, Low-Reductase, a recombinant CYP3A7, a major fetal‐type P450 enzyme is mainly expressed in the human fetal liver and intestine .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113327

1,3,7-Trimethyluric acid	Natural Products Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite
1,3,7-Trimethyluric acid is the metabolite of caffeine. The metabolic ratio 1,3,7-Trimethyluric acid to caffeine can be evaluated as a biomarker to describe variability in CYP3A activity in a cohort .

HY-N0693

Schisandrin A 5+ Cited Publications Schizandrin-A; Wuweizisu-A; Deoxyschizandrin	Structural Classification Classification of Application Fields Source classification Lignans Phenylpropanoids Plants Schisandraceae Schisandra chinensis (Turcz.) Baill. Disease Research Fields Cancer	Cytochrome P450 Autophagy Virus Protease
Schisandrin A inhibits *CYP3A* activity with an IC₅₀ of 6.60 μM and K_i of 5.83 μM, respectively.

HY-N0692

Schisandrol B 2 Publications Verification Gomisin-A; TJN-101; Wuweizi alcohol-B	Structural Classification Classification of Application Fields Source classification Lignans Phenylpropanoids Plants Schisandraceae Schisandra chinensis (Turcz.) Baill. Disease Research Fields Cancer	Reactive Oxygen Species Cytochrome P450 Autophagy
Schisandrol B (Gomisin-A) is a major active constituent of Schisandra chinensis with hepato-protective effects. Schisandrol B inhibits reactive oxygen species (ROS) production. Schisandrol B inhibits the activity of P-glycoprotein and *CYP3A* and also has anti-inflammatory, anti-diabetic and antioxidant activities ^[3].

HY-N1457

Chrysosplenetin	Flavonols Structural Classification Piscidia erythrina L. Flavonoids Classification of Application Fields Source classification Phenols Polyphenols Metabolic Disease Plants Compositae Disease Research Fields	P-glycoprotein Cytochrome P450 Ferroptosis
Chrysosplenetin is one of the polymethoxylated flavonoids in Artemisia annua L. (Compositae) and other several Chinese herbs. Chrysosplenetin inhibits P-gp activity and reverses the up-regulated P-gp and MDR1 levels induced by artemisinin (ART). Chrysosplenetin significantly augments the rat plasma level and anti-malarial efficacy of ART, partially due to the uncompetitive inhibition effect of Chrysosplenetin on rat *CYP3A* .

HY-113482

1β-Hydroxydeoxycholic acid 1β-OH-DCA	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite Cytochrome P450
1β-Hydroxydeoxycholic acid (1β-OH-DCA), a secondary bile acid, is a CYP3A biomarker. Deoxycholic acid is specifically metabolized into 1β-Hydroxydeoxycholic acid by CYP3A4 and CYP3A7 using recombinant human CYP450 enzymes .

HY-N0693R

Schisandrin A (Standard)	Structural Classification Source classification Lignans Phenylpropanoids Plants Schisandraceae Schisandra chinensis (Turcz.) Baill.	Cytochrome P450 Autophagy Virus Protease
Schisandrin A (Standard) is the analytical standard of Schisandrin A. This product is intended for research and analytical applications. Schisandrin A inhibits CYP3A activity with an IC₅₀ of 6.60 μM and Ki of 5.83 μM, respectively.

HY-N0692R

Schisandrol B (Standard)	Structural Classification Source classification Lignans Phenylpropanoids Plants Schisandraceae Schisandra chinensis (Turcz.) Baill.	Reactive Oxygen Species Cytochrome P450 Autophagy
Schisandrol B (Standard) is the analytical standard of Schisandrol B. This product is intended for research and analytical applications. Schisandrol B (Gomisin-A) is a major active constituent of Schisandra chinensis with hepato-protective effects. Schisandrol B inhibits reactive oxygen species (ROS) production. Schisandrol B inhibits the activity of P-glycoprotein and CYP3A and also has anti-inflammatory, anti-diabetic and antioxidant activities ^[3].

HY-N7454

Anhydroerythromycin A	Infection Structural Classification Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Antibacterial Disease Research Endogenous metabolite Disease Research Fields	Antibiotic Bacterial
Anhydroerythromycin A is a degradation product of the macrolide antibiotic erythromycin. Anhydroerythromycin A is formed via degradation of erythromycin in acidic aqueous solutions in vitro as well as in vivo. Anhydroerythromycin A is active against S. aureus and B. cereus in vitro (MICs = 12.5 and 6.25 μg/ml, respectively). Anhydroerythromycin A also inhibits steroid 6β-hydroxylase activity associated with the cytochrome P450 (CYP) isoform CYP3A in human liver microsomes.

HY-N7454R

Anhydroerythromycin A (Standard)	Structural Classification Macrolide Antibiotics Antibiotics Source classification Antibacterial Disease Research Endogenous metabolite	Antibiotic Bacterial
Anhydroerythromycin A (Standard) is the analytical standard of Anhydroerythromycin A. This product is intended for research and analytical applications. Anhydroerythromycin A is a degradation product of the macrolide antibiotic erythromycin. Anhydroerythromycin A is formed via degradation of erythromycin in acidic aqueous solutions in vitro as well as in vivo. Anhydroerythromycin A is active against S. aureus and B. cereus in vitro (MICs = 12.5 and 6.25 μg/ml, respectively). Anhydroerythromycin A also inhibits steroid 6β-hydroxylase activity associated with the cytochrome P450 (CYP) isoform CYP3A in human liver microsomes.

HY-113327R

1,3,7-Trimethyluric acid (Standard)	Natural Products Human Gut Microbiota Metabolites Microorganisms Source classification Endogenous metabolite	Drug Metabolite Endogenous Metabolite
Hederagenin (Standard) is the analytical standard of Hederagenin. This product is intended for research and analytical applications. Hederagenin is a triterpenoid saponin with orally active and antitumor activity. Hederagenin can inhibit the expression of iNOS, COX-2, and NF-κB in cells induced by LPS stimulation. Hederagenin also increases ROS production in cancer cells, disrupts mitochondrial membrane potential, and induces apoptosis. Hederagenin also sensitizes cancer cells to Cisplatin (HY-17394) and Paclitaxel (HY-B0015), enhancing induced apoptosis. Hederagenin also has preventive potential against alcoholic liver injury ^[3] .

Cat. No.	Product Name	Chemical Structure

HY-10493S

Cobicistat-d8
Cobicistat-d8 (GS-9350-d8) is a deuterated version of Cobicistat (HY-10493). Cobicistat is a potent and selective inhibitor of cytochrome P450 3A (CYP3A) with IC₅₀ values of 30-285 nM. Cobicistat is a pharmacokinetic enhancer that enhances the absorption of anti-HIV active molecules ^[3].

HY-130353S

Desethyl Amiodarone-d4 hydrochloride

Desethyl Amiodarone-d₄ (hydrochloride) is the deuterium labeled Desethylamiodarone hydrochloride. Desethylamiodarone hydrochloride (N-desethylamiodarone hydrochloride) is a major active metabolite of Amiodarone. Desethylamiodarone hydrochloride is formed by CYP3A isoenzymes. Amiodarone is an antiarrhythmic agent for inhibition of ATP-sensitive potassium channel with an IC50 of 19.1 μM[1][2][3].

HY-117580S

16α-Hydroxyprednisolone-d3
16α-Hydroxyprednisolone-d₃ is the deuterium labeled 16α-Hydroxyprednisolone. 16α-Hydroxyprednisolone is a stereoselective metabolite of the 22(R) epimer of the glucocorticoid budesonide via cytochrome P450 3A (CYP3A) enzymes[1][2].

HY-13463BS

Avatrombopag-d8 hydrochloride

Avatrombopag-d₈ (hydrochloride) is deuterium labeled Avatrombopag (hydrochloride). Avatrombopag (AKR-501) hydrochloride is an orally active, nonpeptide thrombopoietin (TPO) receptor agonist (EC50=3.3 nM). Avatrombopag hydrochloride mimics the biological activities of TPO. Avatrombopag hydrochloride increases platelet production by activating the intracellular signaling system, and promotes production of platelets and megakaryocytes from hemopoietic precursor cells. Avatrombopag hydrochloride is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A[1][2][3].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83620

	Cytochrome P450 3A4 Antibody (YA3365) HLP; CP33; CP34; CYP3A; NF-25; CYP3A3; P450C3; CYPIIIA3; CYPIIIA4; P450PCN1; CYP3A4	WB, IHC-P, IP	Human
	Cytochrome P450 3A4 Antibody (YA3365) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3365), targeting Cytochrome P450 3A4, with a predicted molecular weight of 57 kDa (observed band size: 57 kDa). Cytochrome P450 3A4 Antibody (YA3365) can be used for WB, IHC-P, IP experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks